Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 2

Editorial ||FREE PAPER||

Authors Garry Walsh

Published 15 June 2006 Volume 2006:2(2) Pages 127—128

Garry Walsh

Asthmatic and Allergic Inflammation Group, School of Medicine, University of Aberdeen, UK

The second issue of volume two of Therapeutics and Clinical Risk Management contains a diverse selection of comprehensive review articles and original research papers from leading authors around the world.

Download Article [PDF] 

Readers of this article also read:

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta, Tracy Prematta, Timothy J Craig

Therapeutics and Clinical Risk Management 2008, 4:975-982

Published Date: 10 October 2008

Update on local anesthetics: focus on levobupivacaine

Crina L Burlacu, Donal J Buggy

Therapeutics and Clinical Risk Management 2008, 4:381-392

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Ondansetron oral disintegrating tablets for the prevention of postoperative vomiting in children undergoing strabismus surgery

Deborah S Wagner, Virginia Gauger, Devi Chiravuri, Kristin Faust

Therapeutics and Clinical Risk Management 2007, 3:691-694

Published Date: 15 September 2007

Alendronate sodium in the management of osteoporosis

P J J Prinsloo, DJ Hosking

Therapeutics and Clinical Risk Management 2006, 2:235-249

Published Date: 15 September 2006